Endovascular Engineering
Endovascular Engineering develops and commercializes the FDA-cleared Hēlo Thrombectomy System, a catheter-based mechanical thrombectomy device for treating pulmonary embolism and deep vein thrombosis in hospital interventional cardiology and radiology departments.
- Company typePrivate
- Founded2019
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endovascular Engineering does
Endovascular Engineering, Inc. (E2) is a private medical device company headquartered in Menlo Park, California, that develops mechanical thrombectomy systems for the treatment of venous thromboembolism (VTE). Founded in 2019 and operating with 11–50 employees, the company targets hospital-based interventional cardiology and radiology departments performing procedures for pulmonary embolism (PE) and deep vein thrombosis (DVT). E2 has raised $137 million across three funding rounds (Series A1 in 2022, Series B in early 2025, and an oversubscribed Series C in April 2026) from a syndicate including Gilde Healthcare, Norwest, Santé Ventures, Cordis, S3 Ventures, 415 Capital, Panakès Partners, and M&L Healthcare Investments.
The company's sole commercial product is the Hēlo™ Thrombectomy System, which received FDA 510(k) clearance in late 2025 for clot removal from pulmonary arteries and peripheral veins. The device is built around a patented dual-action mechanism that combines high-speed mechanical agitation with physician-controlled simultaneous aspiration, delivered through a small-profile catheter that houses a self-expanding funnel. This architecture is designed to give operators the navigational agility of a small-bore catheter while matching the clot-engagement performance of large-bore devices, enabling single-pass clot removal in complex anatomies with reduced hemodynamic impact. Clinical evidence is anchored by the ENGULF IDE program (feasibility n=25 plus pivotal cohort), with feasibility data published in JSCAI and pivotal results presented at SIR, SCAI, and VIVA conferences.
E2 generates revenue through direct hardware sales of the Hēlo system to U.S. hospitals, with pricing negotiated through hospital procurement and group purchasing organizations. The company employs an enterprise field sales motion, having recently built out dedicated SVP of Sales, VP of Marketing, and SVP Clinical and Market Development functions to drive adoption at target accounts. As a newly commercial-stage device company, E2 is investing heavily in scaling its commercial organization, funded by the April 2026 Series C. The company is led by CEO Dan Rose, with Founder Luis Savastano, MD, PhD serving as Chief Scientific Officer.
Endovascular Engineering firmographics
Firmographics- Name
- Endovascular Engineering
- Legal name
- Endovascular Engineering, Inc.
- Website
- https://endovascularengineering.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Endovascular Engineering develops and commercializes the FDA-cleared Hēlo Thrombectomy System, a catheter-based mechanical thrombectomy device for treating pulmonary embolism and deep vein thrombosis in hospital interventional cardiology and radiology departments.
- Ownership category
- akta.pro rank
Endovascular Engineering industry classification
Industry- Product category
- Interventional Cardiology & Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industry
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
Keywords
Where Endovascular Engineering is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Endovascular Engineering business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure
Revenue model
- Hēlo Thrombectomy System (Hardware Sales): E2 generates revenue from the sale of its FDA-cleared Hēlo Thrombectomy System to hospital interventional cardiology and radiology departments. As a commercial-stage medical device company, revenue is derived from direct product sales to healthcare providers for use in pulmonary embolism and venous thrombectomy procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Endovascular Engineering product offering
Product offeringCore offering
Endovascular Engineering develops and commercializes the Hēlo™ Thrombectomy System, an FDA-cleared mechanical thrombectomy catheter for the treatment of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. The catheter-based system combines aspiration with mechanical clot disruption via a self-expanding funnel design, enabling small-profile navigation with large-bore clot engagement in a single-pass procedure.
Product overview
Endovascular Engineering offers a single unified product—the Hēlo™ Thrombectomy System (also referred to as the Hēlo® Thrombectomy Platform or Hēlo® PE Thrombectomy System). This is a medical device platform designed for mechanical thrombectomy treatment of venous thromboembolism (VTE), specifically targeting pulmonary embolism (PE) and deep vein thrombosis (DVT). The system features a patented dual-action mechanism combining aspiration with mechanical clot disruption, housed in a small-profile catheter with a self-expanding funnel that expands for effective large bore clot engagement. The device received FDA 510(k) clearance in late 2025 and is now in commercial stage.
Differentiator
Problem solved
Functional benefit
Products and services
- Hēlo™ PE Thrombectomy System A next-generation mechanical thrombectomy catheter system for treating venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Features a self-expanding funnel design and dual-action technology combining high-speed agitation with physician-controlled aspiration for single-pass clot removal, intended for use by interventional cardiologists and radiologists in hospital settings.
Quantifiable outcome
- Feasibility study demonstrated safety and feasibility in 25 intermediate-risk PE patients
- +1 more outcomes
Companies that use Endovascular Engineering
Customer profileSegments1 record
Ideal customer profiles1 record
Endovascular Engineering technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Endovascular Engineering partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor.
- Eric Secemsky, MD, MScminorDirector of Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. Listed as a Key Clinical Partner on the company About page, providing clinical advisory and validation for the Hēlo platform.
- Jay Giri, MD, MPHminorNational Principal Investigator for the ENGULF feasibility study. Listed as a Key Clinical Partner on the company About page. Published clinical data supporting the Hēlo system in peer-reviewed literature.
- Andrew Klein, MDminorNational co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.
- Julie Bulman, MDminorNational co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.
- Kush Desai, MDminorListed as a Key Clinical Partner on the company About page, providing clinical expertise in interventional radiology for the Hēlo platform.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Endovascular Engineering competitors and assessment
Company assessmentDirect peers
- Inari Medical: Inari Medical (acquired by Stryker for $4.9B in 2025) developed the FlowTriever system for mechanical thrombectomy in PE and DVT. It is the direct competitor to Endovascular Engineering's Hēlo system, targeting the same interventional cardiology and radiology call points with similar catheter-based clot removal technology.
- Penumbra: Penumbra's Indigo and Lightning systems are leading mechanical thrombectomy platforms for PE and peripheral clot removal. It is a direct competitor to Hēlo with a large installed base, established clinical data, and a global hospital sales force.
- AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for PE treatment and is the plaintiff in the active patent infringement suit against Endovascular Engineering. It competes head-to-head with Hēlo in the PE thrombectomy category.
Broad incumbents
- Boston Scientific: Boston Scientific offers the EKOS ultrasound-assisted thrombolysis system for PE and DVT through its peripheral interventions franchise. It is a broad incumbent in interventional cardiology/radiology with the scale and channel access to compete against Hēlo.
- Stryker: Stryker acquired Inari Medical for $4.9B and now owns the FlowTriever platform, making it the dominant player in mechanical thrombectomy. Stryker's Neurovascular division also competes in adjacent stroke intervention devices, giving it a broad incumbency over the thrombectomy space.
- Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular and thrombectomy business, offers stent retriever and aspiration technologies for clot removal. It is a broad incumbent with overlapping capabilities in mechanical thrombectomy across peripheral and neurovascular indications.
- Medtronic: Medtronic's peripheral vascular and cardiac franchises include catheter-based technologies that overlap with Hēlo's addressable market. Its scale, hospital relationships, and ability to bundle across indications make it a powerful indirect competitor and potential acquirer.
- Abbott: Abbott's vascular and structural heart businesses include catheter-based technologies and would be a relevant broad incumbent comparable in scale and channel access for any thrombectomy platform reaching commercial scale.
Emerging players
- Walk Vascular: Walk Vascular develops the JETi mechanical thrombectomy system for peripheral and venous applications. It is an emerging niche player with meaningful but partial overlap to Hēlo in the mechanical thrombectomy category.
- Surmodics: Surmodics has developed catheter-based thrombectomy and drug-delivery coating technologies serving peripheral vascular markets. It is an emerging player with adjacent technology overlap relevant to Endovascular Engineering's catheter platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Endovascular Engineering social profiles
Digital presenceEndovascular Engineering compliance and trust
Trust signalCompliance1 record
Endovascular Engineering financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endovascular Engineering leadership team
Management profileNumber of profiles
Profiles12 records
Endovascular Engineering funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endovascular Engineering M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endovascular Engineering
What does Endovascular Engineering do?
Endovascular Engineering develops and commercializes the Hēlo™ Thrombectomy System, an FDA-cleared mechanical thrombectomy catheter for the treatment of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. The catheter-based system combines aspiration with mechanical clot disruption via a self-expanding funnel design, enabling small-profile navigation with large-bore clot engagement in a single-pass procedure.
Is Endovascular Engineering a public or private company?
Endovascular Engineering is a private company. It is classified as venture growth investor backed and is currently operating.
When was Endovascular Engineering founded?
Endovascular Engineering was founded in 2019. It employs 11 to 50 people.
Where is Endovascular Engineering based?
Endovascular Engineering is headquartered in Menlo Park, United States, in the North America region.
How does Endovascular Engineering make money?
One revenue line is on record: Hēlo Thrombectomy System (Hardware Sales).
Who are Endovascular Engineering's main competitors?
Direct peers on record are Inari Medical, Penumbra and AngioDynamics. Broad incumbents are Boston Scientific, Stryker, Johnson & Johnson (Cerenovus), Medtronic and Abbott. Emerging players are Walk Vascular and Surmodics.
Does Endovascular Engineering have an API?
No public API is recorded for Endovascular Engineering.
What industry is Endovascular Engineering in?
Endovascular Engineering's product category is Interventional Cardiology & Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 339112 and its SIC code is 3841.